UNSPSC 51382401: Bromfenac

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H12BrNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 864P0921DW, chemically known as benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- but generally known as bromfenac, which bears US NIH Compound Identifier 60725. Bromfenac most often comes in base and sodium forms. European Medicines Agency schedules Bromfenac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05913MIG.

UNSPSC 51382401 Bromfenac is a Commodity code that in practice covers a broader pharmaceutical and OTC supply category than its nominal name suggests. State and local governments soliciting under this code are purchasing generic multi-source pharmaceuticals, naloxone, drug deactivation systems, and over-the-counter products through both direct procurement and cooperative purchasing agreements. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving multiple states including Oregon). Recent opportunities emphasize public health and emergency response applications, with procurement structured through fixed-price contracts, RFPs, and RFIs that typically require FDA compliance, cGMP certification, and Drug Supply Chain Security Act adherence.

Geographic activity spans Florida, Texas, Minnesota, and Oregon based on recent solicitations. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response deadline July 26, 2023. The Texas HHS Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs before issuing a formal RFP. The Minnesota Department of Administration, administering MMCAP, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Vendors must typically maintain relationships with authorized wholesalers, carry substantial liability insurance ($2 million to $5 million depending on coverage type), and accept administrative fees or performance penalties built into contract terms.